N. Engl. J. Med. 379, 645–654 (2018).

A humanized antibody therapy is an option for individuals infected with HIV for whom there are limited choices.

Although antiretroviral therapy is able to control HIV in many individuals with the virus, some patients have multidrug-resistant HIV infection.

Ibalizumab is a humanized antibody that blocks the entry of HIV into its target cells by noncompetitive binding. Stanley Lewis and his colleagues enrolled 41 patients with multidrug-resistant HIV and limited treatment options into a 5-week trial using this drug, which has previously been shown to have some efficacy in humans.

They found that 83% of patients had an initial response to the drug, and 43% achieved viral suppression to undetectable levels at 24 weeks.